Skip to main content

Table 1 Summary of baseline characteristics of 53 Caucasian postmenopausal women

From: Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene

 

mean (SD)

Range

Age (year)

59.7 (6.2)

39.0 – 69.0

Years postmenopausal (year)

13.1 (6.9)

5.0 – 38.0

BMI (kg/m 2 )

25.6 (3.4)

18.9 – 34.9

SBP (mmHg)

143.4 (17.8)

105.0 – 190.0

DBP (mmHg)

85.5 (10.0)

60.0 – 105.0

BALP (μg/L)

12.2 (5.3)

4.9 – 29.1

OC (ng/mL)

33.5 (11.3)

10.0 – 60.3

CTX (ng/mL)

0.52 (0.19)

0.12 – 0.89

BUA (dB/MHz)

54.8 (11.5)

33.8 – 85.9

SOS (m/s)

1,513.5 (21.1)

1,464.4 – 1,562.6

QUI

72.0 (12.7)

43.9 – 104.9

BMD-HIP(g/cm 2 )

0.727 (0.096)

0.472 – 0.910

BMD-FN(g/cm 2 )

0.627 (0.076)

0.420 – 0.840

BMD-LS (g/cm 2 )

0.759 (0.071)

0.586 – 0.950

HOL (mmol/L)

5.85 (0.78)

4.31 – 7.37

HDL (mmol/L)

1.65 (0.31)

1.19 – 2.36

LDL (mmol/L)

3.53 (0.67)

2.17 – 4.81

TG (mmol/L)

1.50 (0.72)

0.67 – 4.03

  1. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; BALP, serum bone-specific alkaline phosphatase; OC, serum osteocalcin; CTX, serum C-terminal telopeptide fragments of type I collagen; BUA, broadband ultrasound attenuation; SOS, heel speed of sound; QUI, quantitative ultrasound index; BMD-HIP, bone mineral density of total hip; BMD-FN, bone mineral density of femoral neck; BMD-LS, bone mineral density of lumbar spine.